A massive genomic study has linked mutations in a single gene to a striking health profile: an increased proportion of muscle, less belly fat, lower blood sugar, and a reduced risk of conditions including type 2 diabetes and heart disease.
The gene, called FNIP1, helps cells sense and respond to nutrients. Researchers led by the Regeneron Genetics Center sequenced more than one million genomes from diverse backgrounds across three continents, then searched for variants tied to the TG:HDL ratio — a blood biomarker where higher values signal greater metabolic risk.
Variants stood out in FNIP1. Only about one in 7,000 people carried one of the newly identified protective variants, but those who did showed markedly healthier metabolism — including, on average, a 60% lower risk of cardiometabolic disease, a basket of interconnected conditions spanning stroke, diabetes, heart attack and some liver diseases.
"These diseases are the number one cause of death in the world, and they have a strong genetic basis," said Luca Lotta of the Regeneron Genetics Center, a co-author of the study published today in Nature.
The team then followed the genetic clues into the lab: silencing FNIP1 and related genes in human liver cells boosted expression of genes involved in breaking up lipids, and the same intervention in mice prevented disease.
For the vast majority of people who lack the rare protective variants, the findings offer more than reason for envy — they reveal a possible drug target. A medication that mimics the variants' effects could one day reproduce some of their apparent protection against the world's leading cause of death.
